Psoriatic arthritis (PsA)
- Match therapy to joints, skin, enthesitis + axial disease
- NSAID for mild symptomatic disease
- DMARD for persistent peripheral arthritis
- TNF/IL-17/IL-23 or targeted oral therapy for active disease
- Skin severity can drive biologic choice
- Treat to low disease activity/remission
Use at a glance
- Match therapy to joints, skin, enthesitis + axial disease
Treatment options
- DMARD for persistent peripheral arthritis
- TNF/IL-17/IL-23 or targeted oral therapy for active disease
Practical pearls
- Skin severity can drive biologic choice
- Treat to low disease activity/remission
Other practical pearls
- NSAID for mild symptomatic disease
Self-check
- What clinical domains should guide PsA therapy?
Joints, skin, enthesitis, and axial disease.
- What is used for active PsA needing advanced therapy?
TNF/IL-17/IL-23 or targeted oral therapy.
Drugs used for this (9)
All clinical uses · Open the interactive console ↗
